Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on VYNE Therapeutics and keeping the price target at $6.00.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rami Katkhuda’s rating is based on the promising potential of VYNE Therapeutics’ repibresib gel, which is currently undergoing a Phase IIb study. The study is testing higher concentrations of the gel, which could enhance its efficacy while maintaining a favorable safety profile. The ongoing trial is also extending the evaluation period to 24 weeks and includes both active and stable disease subjects, potentially offering a competitive edge over existing JAK inhibitors.
Katkhuda believes that if repibresib demonstrates efficacy comparable to Incyte’s Opzelura by the 24-week mark, it could significantly boost VYNE’s stock value. Additionally, the once-daily administration and anticipated absence of a black box warning make repibresib an attractive first-line treatment option in the expanding nonsegmental vitiligo market, provided its clinical benefits are on par with current therapies.
In another report released on July 3, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.50 price target.